76 citations
,
August 2007 in “Supportive care in cancer” The researchers reported that dermatological side effects from chemotherapy for women's cancers are common and significantly affect quality of life.
12 citations
,
May 2015 in “Journal of the National Comprehensive Cancer Network” This article provides a narrative on managing dermatologic side effects from cancer therapies and suggests strategies that oncologists could adopt, but it reports no new clinical findings.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” This study reports that 71% of patients treated with the gamma-secretase inhibitor PF-03084014 for desmoid tumors experienced dermatologic side effects, such as follicular lesions and pruritic eruptions, which were managed with topical or systemic treatments.
86 citations
,
November 2020 in “Annals of Oncology” These guidelines discuss prevention and management strategies for dermatological toxicities but report no new clinical results; they include expert recommendations for conditions like acneiform rash and hand-foot syndrome.
9 citations
,
December 2018 in “Cutaneous and Ocular Toxicology” This meta-analysis found that combined BRAF and MEK inhibitor treatment in melanoma patients is linked to increased all-grade rash but reduced risks of several other dermatological toxicities compared to BRAF inhibition alone.